Mirum Pharmaceuticals’ (MIRM) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Mirum Pharmaceuticals (NASDAQ:MIRM) in a report published on Monday morning, Benzinga reports. They currently have a $66.00 target price on the stock.

Several other equities research analysts have also commented on MIRM. Citigroup upped their target price on Mirum Pharmaceuticals from $38.00 to $64.00 and gave the company a buy rating in a research report on Tuesday, June 18th. Cantor Fitzgerald reiterated an overweight rating and issued a $40.00 price target on shares of Mirum Pharmaceuticals in a report on Thursday, May 9th. JMP Securities increased their price target on Mirum Pharmaceuticals from $66.00 to $68.00 and gave the stock a market outperform rating in a report on Tuesday, June 18th. SVB Leerink cut their price target on Mirum Pharmaceuticals from $44.00 to $43.00 and set an outperform rating on the stock in a report on Monday, March 18th. Finally, Baird R W upgraded Mirum Pharmaceuticals to a strong-buy rating in a report on Monday, June 17th. Ten equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of Buy and an average target price of $53.64.

Mirum Pharmaceuticals Trading Up 4.8 %

NASDAQ MIRM opened at $37.66 on Monday. Mirum Pharmaceuticals has a 12 month low of $23.14 and a 12 month high of $37.90. The company has a current ratio of 3.68, a quick ratio of 3.47 and a debt-to-equity ratio of 1.31. The business’s 50-day moving average price is $28.49 and its two-hundred day moving average price is $27.50. The firm has a market capitalization of $1.78 billion, a PE ratio of -10.15 and a beta of 1.15.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its earnings results on Wednesday, May 8th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.14). Mirum Pharmaceuticals had a negative net margin of 69.67% and a negative return on equity of 56.46%. The business had revenue of $69.22 million for the quarter, compared to the consensus estimate of $69.71 million. On average, analysts expect that Mirum Pharmaceuticals will post -1.66 EPS for the current year.

Insider Buying and Selling at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, Director Saira Ramasastry sold 5,000 shares of the stock in a transaction on Wednesday, June 5th. The stock was sold at an average price of $25.68, for a total transaction of $128,400.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, insider Pamela Vig sold 30,559 shares of Mirum Pharmaceuticals stock in a transaction on Monday, June 24th. The stock was sold at an average price of $34.00, for a total transaction of $1,039,006.00. Following the completion of the sale, the insider now owns 27,406 shares of the company’s stock, valued at $931,804. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Saira Ramasastry sold 5,000 shares of Mirum Pharmaceuticals stock in a transaction on Wednesday, June 5th. The shares were sold at an average price of $25.68, for a total value of $128,400.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 35,934 shares of company stock valued at $1,180,156. Company insiders own 22.87% of the company’s stock.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. AJOVista LLC purchased a new stake in Mirum Pharmaceuticals during the fourth quarter valued at about $40,000. Wetzel Investment Advisors Inc. purchased a new stake in Mirum Pharmaceuticals during the fourth quarter valued at about $41,000. StepStone Group LP purchased a new stake in Mirum Pharmaceuticals during the fourth quarter valued at about $135,000. China Universal Asset Management Co. Ltd. raised its position in Mirum Pharmaceuticals by 447.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,394 shares of the company’s stock valued at $159,000 after purchasing an additional 4,408 shares in the last quarter. Finally, Quest Partners LLC purchased a new stake in Mirum Pharmaceuticals during the fourth quarter valued at about $194,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.